Moderna (MRNA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 6, 2026 | $0.38 | $-1.22 | 131.2 % |
| Q2 | Jul 31, 2026 | $-1.97 | $-2.07 | 4.83 % |
| Q1 | May 1, 2026 | $-1.18 | $-3.71 | 68.2 % |
| Q4 | Feb 13, 2026 | $-2.11 | $-2.60 | 18.9 % |
Quarterly Revenue (Billions)
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 6, 2026 | $1.31B | $889.93M | 47.5 % |
| Q2 | Jul 31, 2026 | $145.00M | $104.40M | 38.9 % |
| Q1 | May 1, 2026 | $389.00M | $233.79M | 66.4 % |
| Q4 | Feb 13, 2026 | $678.00M | $638.92M | 6.12 % |
Moderna (MRNA) publicó su última previsión de noviembre 12, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $2.24B - $2.43B para el período.
En comparación con la previsión anterior, Moderna mantenido redujo su previsión de ingresos desde un rango anterior de $2.24B - $2.43B.
Moderna ha emitido 15 actualizaciones de orientación entre el noviembre 2, 2023 y el noviembre 12, 2026. During this period, the company raised its outlook 3 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.22 | $-2.07 | $-3.71 | $-2.60 |
| Actual | $0.38 | $-1.97 | $-1.18 | $-2.11 |
| Surprise | +131.2% | +4.83% | +68.2% | +18.9% |
| Revenue | ||||
| Estimate | $889.9M | $104.4M | $233.8M | $638.9M |
| Actual | $1.31B | $145.0M | $389.0M | $678.0M |
| Surprise | +47.5% | +38.9% | +66.4% | +6.12% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-2.19 | $-1.79 | $-2.05 | $0.33 |
| Revenue | ||||
| Consensus | $588.4M | $262.8M | — | — |
